Arbutus Biopharma Corporation (ABUS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.08+0.09 (+2.84%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close2.99
Bid0.00 x
Ask5.20 x 400
Day's Range2.96 - 3.11
52wk Range2.72 - 6.26
1y Target EstN/A
Market Cap168.77M
P/E Ratio (ttm)-0.86
Avg Vol (3m)125,652
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire2 days ago

    Patrick Machado Joins Board of Directors of Roivant Sciences

    HAMILTON, Bermuda, Oct. 19, 2016 /PRNewswire/ -- Roivant Sciences Ltd., an innovative biopharmaceutical company focused on developing promising drug candidates to improve the lives of patients and their families, has expanded its Board of Directors through the appointment of Patrick Machado as its second independent director. Prior to joining the board of Roivant Sciences, Mr. Machado was a co-founder of Medivation and served as its Chief Financial Officer from 2004 to 2014. "We are delighted to welcome Patrick Machado to our board," said Vivek Ramaswamy, Founder and Director of Roivant Sciences.

  • Alnylam Halts Drug Testing After 18 Deaths; Value Seen In Cousin Drug
    Investor's Business Daily15 days ago

    Alnylam Halts Drug Testing After 18 Deaths; Value Seen In Cousin Drug

    Alnylam stock tanked Thursday after the drugmaker ended testing on an amyloidosis drug after several patients died.

  • MarketWatch15 days ago

    Alnylam’s discontinued drug raises bigger question about buzzy RNAi approach

    Wall Street is scattered all over the map in its effort to gauge the effect.